Icon

PEMAZYRE (nda213736)- (4.5MG,9MG,13.5MG)

PEMIGATINIB INCYTE CORP
4.5MG,9MG,13.5MG
Yes No
2040-Aug-30 2025-Apr-17
None None
None No
PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
0 0 0
Total Other Developers 3
Drugs with Suitability No
4.5MG ** ** - - -
9MG ** ** - - -
13.5MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.